Yonghe Medical Group Co (FRA:L97) EBIT: €23.4 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:L97 Yonghe Medical Group Co Ltd FRA:L97
84 GF Score
Price €0.26
GF Value €0.21
! 7 Warning Signs
View Full Analysis

What is Yonghe Medical Group Co EBIT?

Yonghe Medical Group Co FRA:L97 -1.53% 84 EBIT is €23.4 Mil as of Jun. 2026. GuruFocus rates FRA:L97 with a GF Score™ of 84/100 and a GF Value™ of €0.21. The stock has 7 warning signs investors should review.

Yonghe Medical Group Co's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2026 was €14.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was €23.4 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Yonghe Medical Group Co's annualized ROC % for the quarter that ended in Jun. 2026 was 13.14%. Yonghe Medical Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 33.33%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Yonghe Medical Group Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 32.57%.

Yonghe Medical Group Co  (FRA:L97) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Yonghe Medical Group Co's annualized ROC % for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=27.15 * ( 1 - 22.83% )/( (158.889 + 160.02)/ 2 )
=20.951655/159.4545
=13.14 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=206.351 - 10.577 - ( 90.839 - max(0, 66.604 - 103.489+90.839))
=158.889

Invested Capital(Q: Jun. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=222.507 - 14.203 - ( 113.186 - max(0, 76.998 - 125.282+113.186))
=160.02

Note: The Operating Income data used here is two times the semi-annual (Jun. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Yonghe Medical Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=27.904/( ( (86.375 + max(-40.013, 0)) + (81.066 + max(-58.237, 0)) )/ 2 )
=27.904/( ( 86.375 + 81.066 )/ 2 )
=27.904/83.7205
=33.33 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.189 + 1.613 + 9.214) - (10.577 + 0 + 41.452)
=-40.013

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.712 + 1.942 + 0.11399999999999) - (14.203 + 0 + 46.802)
=-58.237

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Yonghe Medical Group Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2026 )
=23.407/71.860
=32.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yonghe Medical Group Co EBIT Related Terms

Yonghe Medical Group Co EBIT Historical Data

* Premium members only.

The historical data trend for Yonghe Medical Group Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yonghe Medical Group Co EBIT Chart

Yonghe Medical Group Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 36.44 -7.89 -68.20 -28.08 15.58

Yonghe Medical Group Co Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.02 -11.67 6.10 9.46 13.95

FRA:L97 vs HCA, THC, DVA: EBIT Comparison

For the Medical Care Facilities subindustry, Yonghe Medical Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Yonghe Medical Group Co EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Yonghe Medical Group Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Yonghe Medical Group Co's EV-to-EBIT falls into.


FRA:L97
84GF Score
Yonghe Medical Group Co Ltd FRA:L97
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Yonghe Medical Group Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €23.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €23.4 Mil mean?
Yonghe Medical Group Co (FRA:L97) has a EBIT of €23.4 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Yonghe Medical Group Co.
Is Yonghe Medical Group Co's EBIT too high?
Yonghe Medical Group Co's current EBIT is €23.4 Mil. Overall, Yonghe Medical Group Co has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does Yonghe Medical Group Co's EBIT compare to HCA and THC?
Yonghe Medical Group Co's EBIT of €23.4 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Yonghe Medical Group Co. Yonghe Medical Group Co's current EBIT is €23.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yonghe Medical Group Co stock overvalued right now?
Yonghe Medical Group Co (FRA:L97) has a current EBIT of €23.4 Mil. The stock's GF Value™ is €0.21, compared to a current price of €0.26 — trading 22.9% above its estimated fair value. The current EBIT is €23.4 Mil. Yonghe Medical Group Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Yonghe Medical Group Co (FRA:L97), the current EBIT is €23.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Yonghe Medical Group Co (FRA:L97) Overvalued in 2026?

Based on GuruFocus' analysis, Yonghe Medical Group Co stock appears to be overvalued. The current stock price of €0.26 is trading 22.9% above its estimated GF Value™ of €0.21.

Key valuation signals for FRA:L97:

  • EBIT: €23.4 Mil
  • GF Value™: €0.21 vs. price of €0.26 (22.9% above fair value)
  • GF Score™: 84/100 with 7 warning signs

No single metric tells the full story. See the FRA:L97 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Yonghe Medical Group Co Business Description

Other Exchanges 02279:Hong Kong
Address Office Tower No. 12B, Chaowai Street, 16th Floor, KunTai International Building, Chaoyang District, Beijing, CHN, 100020
Yonghe Medical Group Co Ltd is a medical group in China that specializes in providing hair-related healthcare services. The company is principally engaged in the provision of hair transplant services. The company generated the majority of its revenue from hair transplant services. The company offers one-stop hair-related healthcare services covering hair transplants, medical hair care, routine hair restoration, and other ancillary services.
84GF Score

Get the complete analysis for FRA:L97

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.26
Price
€0.21
GF Value